Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2021-10-15 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
关于对全资子公司增资并完成工商变更登记的公告
Share Issue/Capital Change Classification · 95% confidence The document is a company announcement regarding an increase in capital investment in a wholly-owned subsidiary and the completion of related business registration changes. It details the amount of capital increase, the purpose, and the updated registration information of the subsidiary. The document is short (729 characters) and focuses on a capital change event rather than financial results or reports. This fits the definition of a Share Issue/Capital Change announcement (SHA).
2021-10-15 Chinese
关于ACYW135群脑膜炎球菌多糖结合疫苗获得Ⅲ期临床试验伦理审查意见书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the receipt of an ethical review opinion letter for the Phase III clinical trial of a vaccine. It discusses the clinical trial progress, regulatory approvals, and future steps but does not contain financial statements, management discussion, or detailed financial data. The document is relatively short (1012 characters) and serves as an update on a clinical trial milestone rather than a financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings related to financial disclosures. It is an announcement about a clinical trial progress, which is best categorized under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-10-11 Chinese
关于股东权益变动的提示性公告
Major Shareholding Notification Classification · 95% confidence The document is a notice about a change in shareholder equity percentages due to the company's stock option plan exercise, which caused an increase in total shares and a passive dilution of certain shareholders' ownership percentages. It explicitly states that the change does not involve a reduction in shares held by the shareholders and does not affect controlling shareholders or actual controllers. The document references a detailed equity change report published elsewhere and is titled as a "提示性公告" (prompting or indicative announcement) about shareholder equity changes. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels or thresholds. The document is short (1245 characters) and is not a full financial report or earnings release, nor is it a regulatory filing or a report publication announcement. Therefore, the best classification is MRQ with high confidence.
2021-09-26 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the change in shareholding percentage of an individual shareholder, Liu Junhui, due to an increase in the company's total shares outstanding, causing his ownership percentage to fall below 5%. The document includes detailed information about the shareholder, the nature of the shareholding change, and compliance with relevant securities laws. There is no financial performance data, earnings information, or management discussion. The content is focused on reporting a change in significant share ownership levels, consistent with notifications required when shareholding crosses thresholds. Therefore, the document fits the category of Major Shareholding Notification (MRQ). The document length and detail confirm it is the report itself, not just an announcement or certification.
2021-09-26 Chinese
关于合作研发的新型冠状病毒mRNA疫苗获得尼泊尔Ⅲ期临床试验批件的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about receiving approval for Phase III clinical trials of a new mRNA COVID-19 vaccine in Nepal. It includes details about the clinical trial approval, regulatory bodies involved, and references to prior announcements. The document is short (1374 characters) and primarily serves to inform investors and the public about this regulatory milestone and the associated risks. It does not contain financial statements, detailed financial analysis, or comprehensive report content. It is not a full annual or interim report, nor is it a call transcript or management discussion. It is an official announcement related to regulatory approval and clinical trial progress, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-09-22 Chinese
关于2018年股票期权激励计划预留授予股票期权第一个行权期采用自主行权模式的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the exercise of stock options under the company's 2018 stock option incentive plan. It includes specifics about the number of options, exercise price, exercise period, conditions met, and the impact on the company's share capital and financials. It is not a full financial report but a regulatory announcement about stock option exercise and related corporate actions. The document is longer than 5,000 characters and contains substantive information about the stock option exercise event, not just a brief notice or a report publication announcement. This fits best under the category of Capital/Financing Update (CAP), as it relates to changes in capital structure due to stock option exercises and financing activities.
2021-09-10 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.